{"filing":{"accession_number":"0001104659-26-085235","cik":"0001566044","ticker":"VYNE","company_name":"VYNE Therapeutics Inc.","form":"8-K","filing_date":"2026-07-21","report_date":null,"primary_document":"tm2620874d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926085235/tm2620874d1_8k.htm"},"events":[{"id":18979,"run_id":17079,"accession_number":"0001104659-26-085235","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"VYNE Therapeutics disclosed the imminent closing of a proposed merger with Yarrow Bioscience, expected on or about July 24, 2026. The transaction includes a 1-for-50 reverse stock split and a special cash dividend of $17.3 million ($0.40242 per share) in connection with the merger, along with details on the combined company's post-closing capitalization and trading information.","company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","filing_date":"2026-07-21","form":"8-K","submitted_at":null,"items":[{"id":17947,"accession_number":"0001104659-26-085235","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the imminent closing of a proposed merger between VYNE and Yarrow Bioscience, expected on or about July 24, 2026. The press release announces a 1-for-50 reverse stock split and a special cash dividend of $17.3 million ($0.40242 per share) in connection with the merger, along with details on the combined company's post-closing capitalization and trading information. This is a material acquisition/change of control event that would significantly affect investor assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T12:15:42.629088+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17948,"accession_number":"0001104659-26-085235","item_number":"8.01","item_title":"Other Events.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This Item 8.01 disclosure announces stockholder approval and board approval of a 1-for-50 reverse stock split in connection with the pending Yarrow merger, along with details on a special cash dividend of $17.3 million (~$0.40242 per share). While the reverse stock split is a governance/capital structure matter and the dividend is a financial distribution, the disclosure is primarily governance-focused (charter amendment, stockholder vote, board action) rather than fitting neatly into a specific financial category. The merger itself (ma_activity) is the underlying transaction, but this Item centers on the reverse split mechanics and dividend announcement as discrete corporate actions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T12:15:42.629088+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17947,"accession_number":"0001104659-26-085235","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the imminent closing of a proposed merger between VYNE and Yarrow Bioscience, expected on or about July 24, 2026. The press release announces a 1-for-50 reverse stock split and a special cash dividend of $17.3 million ($0.40242 per share) in connection with the merger, along with details on the combined company's post-closing capitalization and trading information. This is a material acquisition/change of control event that would significantly affect investor assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T12:15:42.629088+00:00","company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","filing_date":"2026-07-21"},{"id":17948,"accession_number":"0001104659-26-085235","item_number":"8.01","item_title":"Other Events.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This Item 8.01 disclosure announces stockholder approval and board approval of a 1-for-50 reverse stock split in connection with the pending Yarrow merger, along with details on a special cash dividend of $17.3 million (~$0.40242 per share). While the reverse stock split is a governance/capital structure matter and the dividend is a financial distribution, the disclosure is primarily governance-focused (charter amendment, stockholder vote, board action) rather than fitting neatly into a specific financial category. The merger itself (ma_activity) is the underlying transaction, but this Item centers on the reverse split mechanics and dividend announcement as discrete corporate actions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T12:15:42.629088+00:00","company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","filing_date":"2026-07-21"}]}